The main news is a broader ARCHER II success framework, not new efficacy data. Annexon added a Month 24 dual primary endpoint while keeping the Month 15 endpoint intact, meaning the trial can potentially demonstrate protection against vision loss at either independent timepoint. The company says masked event accrual remains on schedule, but the filing provides no unmasked efficacy result yet. (Exhibit 99.2 — ARCHER II trial update)
The near-term catalyst is unchanged, while the longer-term evidence package gets stronger. The independent Data Monitoring Committee is still expected to assess the Month 15 endpoint in Q4 2026. If Month 15 succeeds, the planned sub-study analyses could follow in Q1 2027; otherwise, the trial may continue to the Month 24 analysis, with full ARCHER II completion expected in Q3 2027. The addition improves the potential label-supporting duration of evidence, but it does not remove the central binary risk around the upcoming Month 15 readout. (Exhibit 99.2 — ARCHER II trial milestones)
The financial quarter itself was slightly below the limited published EPS expectation. Reported loss per share was $0.28 versus a published consensus of roughly $0.24 loss per share, a narrow miss. Spending remained elevated as Phase 3 development progressed, with R&D expense up to $46.6 million from $44.2 million year over year and G&A up to $10.6 million from $7.6 million. (Condensed Consolidated Statements of Operations; Financial Results)
| Metric | Q2 2026 | Q2 2025 / comparison | Market expectation |
|---|---|---|---|
| Net loss attributable to common stockholders | $55.3M | $51.0M | — |
| Loss per share | $0.28 | $0.34 | ~$0.24 loss |
| R&D expense | $46.6M | $44.2M | — |
| G&A expense | $10.6M | $7.6M | — |
| Cash, cash equivalents and short-term investments | $209.2M | — | — |
Funding reduces the immediate financing overhang but comes with debt. Annexon entered a credit facility of up to $200 million and drew $50 million initially; combined with $209.2 million of cash, cash equivalents and short-term investments, management expects funding into 2028. That is useful ahead of several clinical and regulatory milestones, although the filing does not quantify the facility’s interest burden or future draw conditions. (Corporate Updates; Cash and operating runway)
Net read: strategically constructive, but not a clean beat. The new Month 24 endpoint adds a potentially valuable longer-term efficacy and labeling opportunity without changing the Q4 2026 Month 15 timetable. Against that, there is still no new clinical efficacy result, the quarter’s EPS was slightly worse than consensus, and the definitive program completion remains in 2027. The result therefore lands as mixed rather than clearly positive.
Read the original 8-K on SEC EDGAR ↗